A new application about

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.5908-62-3, you can also check out more blogs about5908-62-3

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 5908-62-3, name is 1,1-Dioxo-isothiazolidine, introducing its new discovery. 5908-62-3

This application relates to compounds of Formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.5908-62-3, you can also check out more blogs about5908-62-3

Reference£º
Quinuclidine – Wikipedia,
Quinuclidine | C7H555N | ChemSpider